Programme

06h30 Fun run/walk
08h30 – 10h25 Plenary Session
08h30-08h40 Welcome and introduction
08h40-12h30 Industry-sponsored breakfast symposium (Novartis) – Myeloproliferative neoplasms:
08h40-09h25 PMF: To transplant or not, and how does Ruxolitinib influence this decision? – Prof Claire Harrison
09h25-10h10 Difficult clinical scenarios in polycythemia – Prof Claire Harrison
10h10-10h25 Discussion and questions
10h25-10h45 Tea break
10h45-11h30 The changing treatment landscape or Chronic Myeloid Leukemia (CML) – Prof Guiseppe Saglio
11h30-12h15 “Cure” in CML: From timing of transplant to treatment-free remission – Prof Guiseppe Saglio
12h15-12h30 Discussion and questions
12h30-13h30 Lunch
13h30-14h30 Proffered papers
14h30-17h15 Parallel sessions
14h30-17h15 Session on Acute Leukemia Nurses symposium
14h30-15h15 AML in the young: Have we moved past standard "7+3"? – Dr Farhad Ravandi-Kashani Nurses symposium
15h15-15h35 Tea break
15h35-16h20 How I treat High risk MDS/AML in the elderly – Dr Farhad Ravandi-Kashani Nurses symposium
17h00-17h15 Discussion and questions  
17h30 AGM
19h00 Gala dinner
08h30-12h20 Industry-sponsored breakfast symposium (Janssen) – “Myeloma” and “WM/MCL"
08h30-09h15 Myeloma with high risk genetics: Available treatment options – Prof Philippe Moreau
09h15-10h00 Newer novel agents and CAR-Ts: Gain vs Cost? – Prof Philippe Moreau
10h00-10h15 Discussion and questions
10h15-10h35 Tea break
10h35-11h20 Treatment of R/R disease in young patients with MCL – Prof Gianluca Gaidano
11h20-12h05 Treatment options in WM: What to choose when? – Prof Gianluca Gaidano
12h05-12h20 Discussion and questions
12h20-13h20 Lunch
13h20-15h15 Diffuse large B-cell lymphoma (Sponsored by Roche)
13h20-14h05 DLBCL: Current standard of care – Dr Andrew Davies
14h05-14h50 DLBCL: Future directions – Dr Andrew Davies
14h50-15h05 Discussion and questions
15h05-15h15 Closing remarks